Search Results 5971-5980 of 28366 for oral

1. Strategy for Improving Stroke Treatment Response - Mayo Clinic

   Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR >1.7. 15. Platelets <100,000/mm3 ...

2. A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps - Mayo Clinic

   ... oral or esophageal lesions/ulcers; Presence of significant swallowing problems; Unable or unwilling to discontinue medications for cramps and/or opiates ...

3. Head and neck cancers - Doctors and departments - Mayo Clinic

   Oral and Maxillofacial Surgery · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology/Oncology · Pediatric Otolaryngology · Pediatrics · Physical ...

4. Head and neck cancers - Doctors and departments - Mayo Clinic

   Oral and Maxillofacial Surgery · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology/Oncology · Pediatric Otolaryngology · Pediatrics · Physical ...

5. Head and neck cancers - Doctors and departments - Mayo Clinic

   Oral and Maxillofacial Surgery · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology/Oncology · Pediatric Otolaryngology · Pediatrics · Physical ...

6. Curriculum - Obstetric Anesthesiology Fellowship (Minnesota) - Mayo Clinic College of Medicine & Science

   ... oral exams. Didactic opportunities are also available through the Obstetrics and Gynecology Residency core curriculum as well as the Maternal Fetal Medicine ...

7. Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women - Mayo Clinic

   Inability to tolerate oral medication. eGFR < 15 ml/ min/ 1.73 m^2. Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular ...

8. In Clinical Trials - Mayo Clinic Research

   ... Oral Anticoagulants for Thromboembolic Prevention in Patients with Congenital Heart Disease Rochester, MN ... placebo for a 6 week period. Oral Tamoxifen vs.

9. A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib - Mayo Clinic

   inability to take oral medication 2. malabsorption syndromes 3. requirement for intravenous alimentation 8. Any active bleeding excluding hemorrhoidal or ...

10. Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation - Mayo Clinic

    oral agent. - Unable or unwilling to swallow study drug. - Uncontrolled intercurrent illness. - Known hypersensitivity to fluoropyrimidine or leucovorin ...